The cost of anal cancer in England: retrospective hospital data analysis and Markov model

BMC Public Health

Sarah T O'Dwyer¹  Karen P Nugent³  Stuart M Carroll²  Stephanie J Stephens⁴  Michael J Tempest⁴  Sam T Keeping² 

[1] The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK;Sanofi Pasteur MSD, Mallards Reach, Bridge Avenue, Maidenhead, Berks SL6 1QP, UK;Faculty of Medicine, University of Southampton, Southampton General Hospital, Mailpoint 801, South Academic Block, Tremona Road, Southampton SO16 6YD, UK;Pharmerit Ltd, Enterprise House, Innovation Way, York YO10 5NQ, UK

关键词: Resource use;    Reimbursement;    England;    Anal cancer;   

Others  :  1123094
DOI  :  10.1186/1471-2458-14-1123

 received in 2014-02-04, accepted in 2014-10-10,  发布年份 2014

【 摘 要 】

Background

Anal cancer requires a multidisciplinary approach to treatment with often complex interventions. Little is known regarding the associated costs and resource use.

Methods

Patient records were extracted from a national hospital database to estimate the number of patients treated for anal cancer in England. Identified resource use was linked to published UK cost estimates to quantify the reimbursement of treatment through the Payment by Results system. A mathematical model was developed simultaneously to validate findings and to calculate the average 10-year cost of treating a squamous cell anal carcinoma case from diagnosis. The model utilised data from the Association of Coloproctology of Great Britain and Ireland's anal cancer position statement.

Results

On average, 1,564 patients were admitted to hospital and 389 attended an outpatient facility per year. The average annual cost per inpatient and outpatient ranged from £4,562-£5,230 and £1,146-£1,335, respectively. Based on the model estimates, the inflated cost per case was between £16,470-£16,652. Results were most sensitive to the mode of admission for primary treatment and the costs of staging/diagnosis (inflated range: £14,309-£23,264).

Conclusions

Despite limitations in the available data, these results indicate that the cost of treating anal cancer is significant. Further observational work is required in order to verify these findings.

【 授权许可】

   
2014 Keeping et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Scholefield JH, Nugent KP: Anal cancer: position statement of the association of coloproctology of Great Britain and Ireland introduction. Colorectal Dis 2011, 13(1):1-2.
• [2]Risk and causes of anal cancer http://cancerhelp.cancerresearchuk.org/type/anal-cancer/about/risks-and-causes-of-anal-cancer webcite
• [3]Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, Ashley RL, Beagrie M, Ryan JA, Corey L: Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987, 317:973-977.
• [4]Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G: Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess 2010, 14:1-101. iii–iv, ix–x
• [5]Cancer statistics registrations http://www.ons.gov.uk/ webcite
• [6]Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ: The epidemiology of anal cancer. Sex Health 2012, 9:504-508.
• [7]Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK: Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010, 24:535-543.
• [8]Kronfli M, Glynne-Jones R: Chemoradiotherapy in anal cancer. Colorectal Dis 2011, 13(Suppl 1):33-38.
• [9]Glynne-Jones R, Northover JMA, Cervantes A: Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v87-v92.
• [10]Renehan AG, Saunders MP, Schofield PF, O’Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg 2005, 92:605-614.
• [11]Renehan AG, O’Dwyer ST: Initial management through the anal cancer multidisciplinary team meeting. Colorectal Dis 2011, 13(Suppl 1):21-28.
• [12]National Institute for Health and Clinical Excellence (NICE): Guidance on Cancer Services. Improving Outcomes in Urological Cancer - The Manual. London, UK: National Institute for Clinical Excellence; 2002:83-85.
• [13]Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775.
• [14]Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J: Option appraisal of population-based colorectal cancer screening programmes in England. Gut 2007, 56:677-684.
• [15]Wolstenholme JL, Whynes DK: Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 1998, 34:1889-1893.
• [16]De Rijke JM, van der Putten HWHM, Lutgens LCHW, Voogd AC, Kruitwagen RFPM, van Dijck JAAM, Schouten LJ: Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996. Eur J Cancer 2002, 38:2041-2047.
• [17]Scholefield JH, Harris D, Radcliffe A: Guidelines for management of anal intraepithelial neoplasia. Colorectal Dis 2011, 13(Suppl 1):3-10.
• [18]Salmo E, Haboubi N: Anal cancer: pathology, staging and evidence-based minimum data set. Colorectal Dis 2011, 13(Suppl 1):11-20.
• [19]Branagan G: Staging and management of inguinal nodes. Colorectal Dis 2011, 13(Suppl 1):29-32.
• [20]Myint AS: Follow up. Colorectal Dis 2011, 13(Suppl 1):39-43.
• [21]Renehan AG, O’Dwyer ST: Management of local disease relapse. Colorectal Dis 2011, 13(Suppl 1):44-52.
• [22]Information Centre: The HES Protocol (June 2009): instructions for handling the data. London: Information Centre; 2009.
• [23]NHS research ethics committee decision tool http://www.hra-decisiontools.org.uk/ethics/ webcite
• [24]Payment by results in the NHS: a simple guide https://www.gov.uk/government/publications/simple-guide-to-payment-by-results webcite
• [25]HRG 4 2010/11 local payment grouper http://www.hscic.gov.uk/article/2332/HRG4-201011-Local-Payment-Grouper-Documentation webcite
• [26]Department of Health: 2010-11 national tariff. 2011. http://data.gov.uk/dataset/payment-by-results-2010-11-national-tariff-information webcite
• [27]2010-11 reference costs https://www.gov.uk/government/publications/2010-11-reference-costs-publication webcite
• [28]Consumer price indices (August dataset) http://www.ons.gov.uk/ons/rel/cpi/consumer-price-indices/august-2012/cpi-time-series-data.html webcite
• [29]Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J: Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010, 102:1123-1128.
• [30]Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall JK, Tamimi H: A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002, 84:263-270.
• [31]De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
• [32]Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009, 124:2375-2383.
• [33]Ogunbiyi OA, Scholefield JH, Robertson G, Smith JH, Sharp F, Rogers K: Anal human papillomavirus infection and squamous neoplasia in patients with invasive vulvar cancer. Obstet Gynecol 1994, 83:212-216.
• [34]Parkin DM, Bray F: Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl 3):S3/11-25.
• [35]Ogunbiyi OA, Scholefield JH, Smith JH, Polacarz SV, Rogers K, Sharp F: Immunohistochemical analysis of p53 expression in anal squamous neoplasia. J Clin Pathol 1993, 46:507-512.